IONS

Over the past six months, Ionis Pharmaceuticals' stock has experienced significant positive movement, increasing by 132.39% from May 7, 2025, to May 6, 2026, and by 169.43% over the last 12 months. Key events impacting the stock price include strong first-quarter 2026 earnings, leading to a 3.73% rise in pre-market trading. The company raised its full-year 2026 revenue guidance to between $875 million and $900 million, an increase of $75 million from previous estimates. Successful launches of Tryngolza and Dawnzera have contributed significantly to revenue growth, and the company increased its annual peak sales estimate for olezarsen (Tryngolza). The company exceeded its 2025 financial guidance due to continued commercial success, primarily driven by Tryngolza product sales and higher royalty revenue.